Matching articles for "Kirsty"
Issue 1743 · December 8, 2025
Insulins for Type 2 Diabetes

The goal of pharmacologic treatment for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration while minimizing hypoglycemia; an A1C goal of <7% is recommended for…

Med Lett Drugs Ther. 2025 Dec 8; 67(1743):196-9 doi:10.58347/tml.2025.1743c
The goal of pharmacologic treatment for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration while minimizing hypoglycemia; an A1C goal of <7% is recommended for most patients to prevent or reduce the microvascular complications of diabetes (retinopathy, nephropathy, neuropathy). An A1C target of <8% may be appropriate for patients who are older, have comorbid conditions, or are at risk for serious hypoglycemia-associated adverse events.
Issue 1743 · December 8, 2025 Free
Comparison Chart: Some Available Insulins for Type 2 Diabetes (online only)

View the Comparison Chart: Some Available Insulins for Type 2 Diabetes

Med Lett Drugs Ther. 2025 Dec 8; 67(1743):e201-4 doi:10.58347/tml.2025.1743d
View the Comparison Chart: Some Available Insulins for Type 2 Diabetes
Issue 1741 · November 10, 2025 Free
In Brief: Kirsty — An Insulin Aspart Interchangeable with NovoLog (online only)

The FDA has approved Kirsty (Biocon), a biosimilar to rapid-acting insulin aspart (NovoLog) , for treatment of type 1 or type 2 diabetes. Kirsty is the first rapid-acting insulin to become available in the US…

Med Lett Drugs Ther. 2025 Nov 10; 67(1741):e185-6 doi:10.58347/tml.2025.1741g
The FDA has approved Kirsty (Biocon), a biosimilar to rapid-acting insulin aspart (NovoLog) , for treatment of type 1 or type 2 diabetes. Kirsty is the first rapid-acting insulin to become available in the US that has received interchangeability status with NovoLog ; Merilog , another insulin aspart biosimilar, was approved earlier but has not received interchangeability status with NovoLog .